Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M609405200 on October 11, 2006

J. Biol. Chem., Vol. 281, Issue 49, 38080-38088, December 8, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/49/38080    most recent
M609405200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rizos, H.
Right arrow Articles by Kefford, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rizos, H.
Right arrow Articles by Kefford, R. F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes*

Helen Rizos{ddagger}1, Heather A. McKenzie{ddagger}, Ana Luisa Ayub{ddagger}, Sarah Woodruff{ddagger}, Therese M. Becker{ddagger}, Lyndee L. Scurr{ddagger}2, Joachim Stahl§, and Richard F. Kefford{ddagger}

From the {ddagger}Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia and the §Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Strasse 10, D-13125 Berlin-Buch, Germany

Alterations in the p14ARF tumor suppressor are frequent in many human cancers and are associated with susceptibility to melanoma, pancreatic cancer, and nervous system tumors. In addition to its p53-regulatory functions, p14ARF has been shown to influence ribosome biogenesis and to regulate the endoribonuclease B23, but there remains considerable controversy about its nucleolar role. We sought to clarify the activities of p14ARF by studying its interaction with ribosomes. We show that p14ARF and B23 interact within the nucleolar 60 S preribosomal particle and that this interaction does not require rRNA. In contrast to previous reports, we found that expression of p14ARF does not significantly alter ribosome biogenesis but inhibits polysome formation and protein translation in vivo. These results suggest a ribosome-dependent p14ARF pathway that regulates cell growth and thus complements p53-dependent p14ARF functions.


Received for publication, October 5, 2006

* This work was supported by the National Health and Medical Research Council, the University of Sydney, and the New South Wales Health Department. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

2 Cameron Melanoma Research Fellow, Melanoma and Skin Cancer Research Institute, University of Sydney.

1 National Health and Medical Research Council RD Wright Fellow, University of Sydney. To whom correspondence should be addressed: Westmead Inst. for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia. Tel.: 61-2-9845-9509; Fax: 61-2-9845-9102; E-mail: helen_rizos{at}wmi.usyd.edu.au.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JEMHome page
I. Robert, F. Dantzer, and B. Reina-San-Martin
Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination
J. Exp. Med., May 11, 2009; 206(5): 1047 - 1056.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement